Pregnancy or breastfeeding
Pregnancy or breastfeeding
. Pregnancy or breastfeeding women.
Pregnancy or active breastfeeding
Pregnancy or breastfeeding.
Pregnancy or breastfeeding
Pregnancy or breastfeeding.
Pregnancy or breastfeeding.
Pregnancy or breastfeeding.
Pregnancy, breastfeeding, or intention of becoming pregnant during the study
Pregnancy or breastfeeding patients.
Pregnancy, lactating or breastfeeding women
Pregnancy or breastfeeding
Pregnancy, breastfeeding or possibility of becoming pregnant during the study.
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding.
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or active breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding.
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Current pregnancy or breastfeeding
Self-reported pregnancy or breastfeeding or planning a pregnancy within the next two years
Pregnancy or breastfeeding
Pregnancy (positive serum ?-HCG) or breastfeeding.
Pregnancy or breastfeeding.
Pregnancy or breastfeeding;
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding;
Current pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Current pregnancy or breastfeeding
Pregnancy or breastfeeding
DONOR: Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or active breastfeeding
Pregnancy or breastfeeding
Self-reported pregnancy or breastfeeding or planning a pregnancy within the next year
Pregnancy or uninterruptible breastfeeding. Pregnancy is an absolute contraindication under this protocol. Women who are breastfeeding must be willing and able to interrupt breastfeeding during the administration of filgrastim and for two days following the final dose.